Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 2/20 | 0.43 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.43 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.42 |
| ▸ | PNLIP | P16233 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 6/20 | 0.42 |
| ▸ | PPARD | Q03181 | 4/20 | 0.42 |
| ▸ | PPARG | P37231 | 3/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL920257 | 0.88 | FAAH (0.47) | PTGER4PTGER2MAP2K1CARM1PRMT6 | |
| SCHEMBL919907 | 0.86 | PTGER4 (0.43) | PTGER4PTGER2CARM1PRMT6SCN9A | |
| SCHEMBL919163 | 0.84 | SCN9A (0.47) | CARM1PRMT6SCN9A | |
| SCHEMBL919178 | 0.84 | SCN9A (0.47) | PTGER4FFAR1CARM1PRMT6SCN9A | |
| SCHEMBL919293 | 0.81 | SCN9A (0.42) | MAP2K1CARM1PRMT6SCN9A | |
| SCHEMBL919807 | 0.79 | CYP2C19 (0.47) | CARM1PRMT6PPARA | |
| SCHEMBL919294 | 0.77 | SLC1A3 (0.44) | CARM1PRMT6SCN9APPARAHIF1A | |
| SCHEMBL5973025 | 0.76 | CARM1 (0.37) | PTGER4MAP2K1FFAR1ACACBCARM1 | |
| SCHEMBL3064569 | 0.76 | MAOB (0.58) | SCN9APPARA | |
| SCHEMBL918991 | 0.75 | MAPK14 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303568-A1 | Substituted 2-Aminoacetamides and the Use Thereof | PURDUE NEUROSCIENCE COMPANY (US) | 2013-11-14 | — | — | US | claimed |
| US-8426431-B2 | Substituted 2-aminoacetamides and the use thereof | PURDUE NEUROSCIENCE COMPANY (US) | 2013-04-23 | — | — | US | claimed |
| EP-2201945-B1 | Use of substituted 2-aminoacetamides for treating or ameliorating anxiety | PURDUE NEUROSCIENCE COMPANY (US) | 2013-03-06 | — | — | EP | claimed |
| EP-2201944-B1 | Use of substituted 2-aminoacetamides for treating, preventing or ameliorating manic depression | PURDUE NEUROSCIENCE COMPANY (US) | 2012-05-23 | — | — | EP | claimed |
| EP-1032377-B1 | SUBSTITUTED 2-AMINOACETAMIDES AND THE USE THEREOF | PURDUE NEUROSCIENCE COMPANY (US) | 2010-11-17 | — | — | EP | claimed |
| EP-2201945-A2 | Substituted 2-Aminoacetamides and the Use Thereof | Purdue Neuroscience Company (US) | 2010-06-30 | — | — | EP | claimed |
| EP-2201944-A2 | Substituted 2-Aminoacetamides and the Use Thereof | Purdue Neuroscience Company (US) | 2010-06-30 | — | — | EP | claimed |
| US-20030130295-A1 | Substituted 2-aminoacetamides and the use thereof | EURO-CELTIQUE S.A. | 2003-07-10 | — | — | US | claimed |
| US-6479484-B1 | SUBSTITUTED 2-AMINOACETAMIDES AND THE DISCOVERY THAT THESE COMPOUNDS ACT AS BLOCKERS OF SODIUM CHANNELS; PAIN RELIEVERS, TREATMENT OF ARRYTHMIA, LOCAL ANESTHETICS | EURO-CELTIQUE S.A. (LU) | 2002-11-12 | — | — | US | claimed |
| US-20020016464-A1 | Substituted 2-aminoacetamides and the use thereof | EURO-CELTIQUE S.A. | 2002-02-07 | — | — | US | claimed |
| US-20130303568-A1 | Substituted 2-Aminoacetamides and the Use Thereof | PURDUE NEUROSCIENCE COMPANY (US) | 2013-11-14 | — | — | US | disclosed |
| US-8426431-B2 | Substituted 2-aminoacetamides and the use thereof | PURDUE NEUROSCIENCE COMPANY (US) | 2013-04-23 | — | — | US | disclosed |
| EP-2201945-B1 | Use of substituted 2-aminoacetamides for treating or ameliorating anxiety | PURDUE NEUROSCIENCE COMPANY (US) | 2013-03-06 | — | — | EP | disclosed |
| EP-2201944-B1 | Use of substituted 2-aminoacetamides for treating, preventing or ameliorating manic depression | PURDUE NEUROSCIENCE COMPANY (US) | 2012-05-23 | — | — | EP | disclosed |
| US-20110269785-A1 | Substituted 2-Aminoacetamides and the Use Thereof | PURDUE NEUROSCIENCE COMPANY (US) | 2011-11-03 | — | — | US | disclosed |
| US-20020037926-A1 | Sodium channel blocker compositions and the use thereof | PURDUE PHARMA LTD. | 2002-03-28 | — | — | US | disclosed |
| WO-2000061188-A9 | SODIUM CHANNEL BLOCKER COMPOSITIONS AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2002-02-14 | — | — | WO | disclosed |
| US-20020016464-A1 | Substituted 2-aminoacetamides and the use thereof | EURO-CELTIQUE S.A. | 2002-02-07 | — | — | US | disclosed |
| EP-1169060-A1 | SODIUM CHANNEL BLOCKER COMPOSITIONS AND THE USE THEREOF | Euro-Celtique S.A. (LU) | 2002-01-09 | — | — | EP | disclosed |
| WO-2000061188-A1 | SODIUM CHANNEL BLOCKER COMPOSITIONS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2000-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303568-A1 | Substituted 2-Aminoacetamides and the Use Thereof | SLC1A2, GAP43, SCN2A | PTGER4 1630/4885PTGER2 726/4885MAP2K1 2806/4885 |
| US-20020037926-A1 | Sodium channel blocker compositions and the use thereof | CACNA1B, CACNB2, CACNA1C | PTGER4 575/4885PTGER2 478/4885MAP2K1 4398/4885 |
| US-20020016464-A1 | Substituted 2-aminoacetamides and the use thereof | SLC1A2, SLC1A1, SCN2A | PTGER4 2616/4885PTGER2 1010/4885MAP2K1 3569/4885 |
| US-20030130295-A1 | Substituted 2-aminoacetamides and the use thereof | SLC1A2, GAP43, SCN2A | PTGER4 1163/4885PTGER2 464/4885MAP2K1 3342/4885 |
| US-20110269785-A1 | Substituted 2-Aminoacetamides and the Use Thereof | SLC1A2, GAP43, SCN2A | PTGER4 1630/4885PTGER2 726/4885MAP2K1 2806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.